These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37936502)

  • 1. What role can LAG-3-blocking antibodies play in melanoma therapy?
    Rutkowski P; Jagodzińska-Mucha P
    Expert Opin Biol Ther; 2023; 23(12):1155-1158. PubMed ID: 37936502
    [No Abstract]   [Full Text] [Related]  

  • 2. Nivolumab and relatlimab for the treatment of melanoma.
    Chen XY; Li YD; Xie Y; Cao LQ; Ashby CR; Zhao H; Chen ZS
    Drugs Today (Barc); 2023 Feb; 59(2):91-104. PubMed ID: 36811409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
    Tawbi HA; Schadendorf D; Lipson EJ; Ascierto PA; Matamala L; Castillo Gutiérrez E; Rutkowski P; Gogas HJ; Lao CD; De Menezes JJ; Dalle S; Arance A; Grob JJ; Srivastava S; Abaskharoun M; Hamilton M; Keidel S; Simonsen KL; Sobiesk AM; Li B; Hodi FS; Long GV;
    N Engl J Med; 2022 Jan; 386(1):24-34. PubMed ID: 34986285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with Nivolumab.
    Thudium K; Selby M; Zorn JA; Rak G; Wang XT; Bunch RT; Hogan JM; Strop P; Korman AJ
    Cancer Immunol Res; 2022 Oct; 10(10):1175-1189. PubMed ID: 35981087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab Plus Relatlimab: First Approval.
    Paik J
    Drugs; 2022 Jun; 82(8):925-931. PubMed ID: 35543970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab/Relatlimab: A Novel Addition to Immune Checkpoint Inhibitor Therapy in Unresectable or Metastatic Melanoma.
    Phillips AL; Reeves DJ
    Ann Pharmacother; 2023 Jun; 57(6):738-745. PubMed ID: 36268952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab + relatlimab for the treatment of unresectable or metastatic melanoma.
    Koseła-Paterczyk H; Rutkowski P
    Expert Opin Biol Ther; 2023 May; 23(5):383-388. PubMed ID: 37200112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CTLA-4-blocking immunotherapy with ipilimumab for advanced melanoma.
    Tarhini AA; Kirkwood JM
    Oncology (Williston Park); 2010 Dec; 24(14):1302, 1304. PubMed ID: 21294474
    [No Abstract]   [Full Text] [Related]  

  • 9. Relatlimab, an Immune Checkpoint Inhibitor that Blocks LAG-3, the Latest Drug to be Added to the Arsenal of Systemic Therapies for Melanoma: What Does a Surgical Oncologist Need to Know?
    van Akkooi ACJ
    Ann Surg Oncol; 2024 Jan; 31(1):1-3. PubMed ID: 37843663
    [No Abstract]   [Full Text] [Related]  

  • 10. Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma.
    Harris-Bookman S; Mathios D; Martin AM; Xia Y; Kim E; Xu H; Belcaid Z; Polanczyk M; Barberi T; Theodros D; Kim J; Taube JM; Burger PC; Selby M; Taitt C; Korman A; Ye X; Drake CG; Brem H; Pardoll DM; Lim M
    Int J Cancer; 2018 Dec; 143(12):3201-3208. PubMed ID: 30248181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal Antibodies for the Treatment of Melanoma: Present and Future Strategies.
    Bhandaru M; Rotte A
    Methods Mol Biol; 2019; 1904():83-108. PubMed ID: 30539467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures.
    Gestermann N; Saugy D; Martignier C; Tillé L; Fuertes Marraco SA; Zettl M; Tirapu I; Speiser DE; Verdeil G
    Oncoimmunology; 2020; 9(1):1736792. PubMed ID: 32850194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of Melanoma.
    Snyder A; Zamarin D; Wolchok JD
    Prog Tumor Res; 2015; 42():22-9. PubMed ID: 26376963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint blockade.
    Naidoo J; Page DB; Wolchok JD
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):585-600. PubMed ID: 24880949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma.
    Albrecht LJ; Livingstone E; Zimmer L; Schadendorf D
    Curr Oncol Rep; 2023 Jun; 25(6):647-657. PubMed ID: 37004702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Treatment of Melanoma: Combined Parasite-Derived Peptide GK-1 and Anti-Programmed Death Ligand 1 Therapy.
    Vera-Aguilera J; Perez-Torres A; Beltran D; Villanueva-Ramos C; Wachtel M; Moreno-Aguilera E; Vera-Aguilera C; Ventolini G; Martínez-Zaguilán R; Sennoune SR
    Cancer Biother Radiopharm; 2017 Mar; 32(2):49-56. PubMed ID: 28301259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiency.
    Bakacs T; Mehrishi JN
    Immunobiology; 2015 May; 220(5):624-5. PubMed ID: 25638260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies].
    Robert C; Mateus C
    Bull Acad Natl Med; 2014 Feb; 198(2):297-308. PubMed ID: 26263705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Newer developments in the immunotherapy of malignant melanoma.
    Maslin B; Alexandrescu DT; Ichim TE; Dasanu CA
    J Oncol Pharm Pract; 2014 Feb; 20(1):3-10. PubMed ID: 23435643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.